US Health-Care Policy Makes Deals ‘Incredibly Hard’, Advent Says

Advent International's managing partner, John Maldonado, stated that U.S. health-care policy creates significant challenges for investors due to unpredictable factors like executive orders that can substantially impact the pharmaceutical industry, making dealmaking difficult. He contrasted this with Europe, where he sees more opportunities in the health-care sector.

Analysis

John Maldonado, managing partner at Advent International, has identified U.S. health-care policy as a significant impediment to investment, characterizing dealmaking as "incredibly hard" due to unpredictable factors like executive orders capable of creating "substantive change in Big Pharma." This assessment, delivered at the SuperReturn private capital conference, carries a moderately negative sentiment (-0.5) and a pessimistic tone, reflecting the challenges faced by private capital in navigating the U.S. regulatory landscape for health-care. In contrast, Maldonado indicated that Europe presents more favorable areas of opportunity within the sector. The situation underscores the heightened idiosyncratic risk stemming from potential policy shifts in the U.S., impacting investor confidence and strategic decision-making in the health-care and biotech industries, particularly for private market participants.

Key Decisions for Investors

• Investors should factor in heightened policy-related risk and uncertainty when evaluating new or existing investments in the U.S. health-care sector, especially within pharmaceuticals.
• Consider re-evaluating geographic allocations within health-care portfolios, potentially exploring opportunities in European markets that may offer a more predictable regulatory environment.
• Closely monitor U.S. executive orders and legislative developments related to health-care, as these can materially impact the outlook and viability of investments in the sector.